{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-22-000179","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.295837+00:00","generated_at":"2026-06-21T23:35:52.099662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023","bullets":["Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.","BLA filing for HAV in vascular trauma anticipated mid 2023; 56 patients enrolled in V005 trial as of Oct 31.","Phase 3 AV access trial nearing completion (227 of 240 enrolled); top-line results 1 yr after enrollment.","Appointed Dr. Cindy Cao as Chief Regulatory Officer and Lt. Gen. C. Bruce Green to Board.","Partnered with Diabetes Research Institute for Biovascular Pancreas program in type 1 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-22-000179","json":"https://secwatch.observer/filing/0001818382-22-000179.json","markdown":"https://secwatch.observer/filing/0001818382-22-000179.md","text":"https://secwatch.observer/filing/0001818382-22-000179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/0001818382-22-000179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/huma-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:35:52.099662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0b333026843fa1b0df7359be82b1e2b6642863b","claim":"Humacyte, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/0001818382-22-000179-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}